Page last updated: 2024-08-23

paclitaxel and Nervous System Disorders

paclitaxel has been researched along with Nervous System Disorders in 74 studies

Research

Studies (74)

Timeframe	Studies, this research(%)	All Research%
pre-1990	3 (4.05)	18.7374
1990's	31 (41.89)	18.2507
2000's	23 (31.08)	29.6817
2010's	15 (20.27)	24.3611
2020's	2 (2.70)	2.80

Authors

Authors	Studies
Boehmerle, W; Endres, M; Huehnchen, P; Muenzfeld, H	1
Ayari, J; Balti, M; Ben Abdallah, I; Ben Hassen, M; Ben Nasr, S; Doghri, Y; Fendri, S; Haddaoui, A; Trigui, E; Zribi, A	1
Mahdi, H; Maurer, K; Michener, C; Rose, PG	1
An, C; Bang, S; Cho, IR; Chung, JB; Chung, MJ; Jo, JH; Jung, SY; Kang, H; Lee, HS; Park, JY; Park, MS; Park, SW; Song, SY	1
Buckley, B; Caffrey, PB; Frenkel, GD; Gibbon, DG; Gounder, M; Hellmann, M; Kane, MP; Kumaran, MN; Nieves-Neira, W; Rodriguez-Rodriguez, L; Shih, W; Song, M; Vaidya, A	1
Benekli, M; Berk, V; Buyukberber, S; Coskun, U; Demirci, U; Ozkan, M; Sevinc, A; Tonyali, O; Ucgul, E; Uncu, D; Yildiz, R	1
Ahmad, FJ; Baas, PW	1
Arena, FP; Bahary, N; Chiorean, EG; Dowden, S; Ervin, T; Goldstein, D; Harris, M; Hidalgo, M; Iglesias, J; Infante, J; Laheru, D; Ma, WW; Moore, M; Ramanathan, RK; Reni, M; Renschler, MF; Saleh, MN; Seay, T; Tabernero, J; Tjulandin, SA; Van Cutsem, E; Von Hoff, DD; Wei, X	1
Bertino, EM; Chatterjee, M; Mo, X; Nana-Sinkam, SP; Otterson, GA; Phillips, GS; Rahmani, M; Shilo, K; Villalona-Calero, MA; Williams, TM	1
Baron, MH; Bessette, P; Colombo, A; Creutzberg, CL; de Boer, SM; Fyles, A; Haie-Meder, C; Katsaros, D; Khaw, P; Kitchener, HC; Kruitwagen, RF; Ledermann, JA; Mileshkin, L; Nijman, HW; Nout, RA; Ottevanger, PB; Powell, ME; Putter, H; Smit, VT; Verhoeven-Adema, KW	1
Bogardus, C; Canfield, V; Hancock, SB; Kaneaster, SK; Kojouri, K; Krempl, GA; Medina, JE	1
Abaid, LN; Brown, JV; Goldstein, BH; Markman, M; Micha, JP; Rettenmaier, MA	1
Clawson, A; Iglesias, J; Krekow, L; O'Shaughnessy, J; Robert, N; Stokoe, C	1
Awad, D; Brafman, L; Crew, KD; Fuentes, D; Hershman, DL; Kranwinkel, G; Wang, A; Weimer, LH	1
Cariello, A; Casanova, C; Cruciani, G; Dazzi, C; Freier, E; Gamboni, A; Leoni, M; Mazza, V; Milandri, C; Montanari, M; Papi, M; Papiani, G; Verlicchi, A; Vertogen, B	1
Green, H; Hasmats, J; Jara, C; Khan, MS; Kupershmidt, I; Lundeberg, J; Mielgo, X; Rodríguez-Antona, C; Su, QJ	1
Davidson, NE; Jones, V; Martino, S; Perez, EA; Saphner, T; Schneider, BP; Sledge, GW; Sparano, JA; Stearns, V; Wang, M; Wolff, AC; Wood, WC; Zhao, F	1
Bergmann, TK; Brosen, K; Eckhoff, L; Feddersen, S; Gréen, H; Herrstedt, J; Vach, W	1
Polee, MB; Siersema, PD; Splinter, TA; Stoter, G; Tilanus, HW; Van der Gaast, A; Verweij, J	1
Andersson, H; Boman, K; Parö, G; Puistola, U; Ridderheim, M; Rosenberg, P; Sorbe, B	1
Baran, I; Coskun, H; Demiray, M; Evrensel, T; Gonullu, G; Kanat, O; Kurt, E; Manavoglu, O; Turan, OF; Zarifoglu, M	1
Brunetto, VL; Burger, RA; Burks, RT; Cella, D; Fleming, GF; Goodman, A; Kline, R; Look, KY; Munkarah, AR; Reid, GC	1
Kim, CH; Kim, HT; Lee, JC; Park, YH; Ryoo, BY	1
Aldrighetti, D; Baldini, E; Bolognesi, A; Bruzzi, P; Carnino, F; Conte, PF; Costantini, M; Giannessi, P; Guarneri, V; Mammoliti, S; Moyano, A; Prochilo, T; Rosso, R; Salvadori, B; Venturini, M	1
Aghajanian, C; Anderson, S; Brown, JV; Dizon, D; Dupont, J; Eisenfeld, AJ; Jacobs, A; Mehdi, A; Peters, WA; Rivkin, S; Sabbatini, P; Spriggs, D	1
Boezen, HM; Bos, AM; de Graaf, H; de Swart, CA; De Vos, FY; de Vries, EG; Schaapveld, M; van der Zee, AG; Willemse, PH	1
Chang, HM; Choi, SJ; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, YH; Ryu, BY	1
Iwabuchi, S; Kashiwagi, H; Takahashi, N; Yamazaki, Y; Yanaga, K	1
Bianchi, G; Capri, G; Caraceni, A; Cundari, S; Gianni, L; Ravaglia, S; Vitali, G; Zanna, C	1
Akerley, W; Choy, H; Egorin, MJ; Glantz, MJ; Kearns, CM	1
Heimans, JJ; Liefting, AJ; Pinedo, HM; Postma, TJ; Vermorken, JB	1
Walker, FE	1
Burroughs, J; Canetta, R; Catane, R; Dougan, M; Grechko, J; Onetto, N; Rozencweig, M; Winograd, B	1
Alakl, M; Clavel, M; Franklin, H; Piccart, M; Prove, AM; Steward, W; ten Bokkel Huinink, WW; Tursz, T; Verweij, J; Wanders, J	1
Catimel, G; Clavel, M; Kerbrat, P; Kerger, J; Tursz, T; van Glabbeke, M; van Hoesel, QG; van Oosterom, AT; van Pottelsberghe, C; Verweij, J	1
Gispen, WH; Hamers, FP; Neijt, JP; Pette, C	1
Bell, DR; Bishop, JF; Friedlander, M; Goldstein, D; Levi, JA; Millward, MJ; Olver, IN; Rischin, D; Smith, JG; Toner, GC	1
Apfel, SC	1
Aghajanian, C; Almadrones, L; Fennelly, D; Gogas, H; Hoskins, WJ; Shapiro, F; Spriggs, DR	1
Bove, L; Innocenti, P; Jandolo, B; Pace, A; Pietrangeli, A	1
Budman, DR; O'Mara, V; Weiselberg, L	1
Dittrich, C; Fazeny, B; Grisold, W; Huber, H; Meryn, S; Zifko, U	1
Hilkens, PH; Pronk, LC; van den Bent, MJ; van Putten, WL; Vecht, CJ; Verweij, J	1
Hande, KR; Johnson, DH; Paul, D	1
Boyd, JH; Dunleavy, TL; Dunphy, CH; Dunphy, FR; Harrison, BR; Hilton, JG; Kim, HJ; McDonough, EM; Minster, JR; Rodriguez, JJ	1
Micha, JP	1
de Swart, C; Engelholm, SA; Hansen, M; Hansen, SW; Hirsch, F; Lund, B; Neijt, JP; Sessa, C; Sørensen, PG; Tuxen, MK; van Houwelingen, HC; Witteveen, PO	1
Edelman, MJ; Houston, J; Lauder, I; Meyers, FJ	1
Aapro, MS	1
Akerley, W; Choy, H; Glantz, M; Joseph, P; Leone, L; Rege, V; Rodrigues, B; Sambandam, S; Wingate, P; Yee, L	1
Armstead, B; Fox, K; Holroyde, C; Malkowicz, SB; Mick, R; Ramchandani, P; Vaughn, DJ; Wein, A; Zoltick, B	1
Antman, K; Ayello, J; Bagiella, E; Balmaceda, C; Dunleavy, J; Fung, B; Garrett, T; Heitjan, D; Hesdorffer, C; Kaufman, E; McGovern, T; Papadopoulos, K; Savage, D; Tiersten, A; Vahdat, LT	1
Bertino, JR; Casper, ES; Ilson, D; Leung, D; Pfister, D; Schwartz, GK; Sugarman, A; Waltzman, RJ; Woodruff, J	1
Booser, DJ; Burris, HA; Earhart, RH; Erban, JK; Esparza-Guerra, L; Holmes, FA; Hortobagyi, GN; Jones, SE; Mennel, RG; Rahman, Z; Ravdin, PM; Schottstaedt, MW; Valero, V; Von Hoff, DD	1
Hilkens, PH; Pronk, LC; Stoter, G; van den Bent, MJ; van Putten, WL; Verweij, J	1
Anagnostopoulos, A; Diakomanolis, E; Dimopoulos, MA; Fountzilas, G; Giannakoulis, N; Gika, D; Moulopoulos, LA; Papadimitriou, CA; Sarris, K; Voulgaris, Z	1
Belani, CP; Selvaggi, G	1
Kerkhofs, L; Kok, TC; Siersema, PD; Splinter, TA; Tilanus, HW; van der Gaast, A	1
Faircloth, GT; Geldof, AA; Henrar, RE; Mastbergen, SC	1
Antonopoulos, MJ; Katsikas, M; Kosmas, C; Malamos, NA; Polyzos, A; Tsavaris, NB	1
Akerley, W	1
Dimopoulos, M; Fountzilas, G; Kalophonos, C; Kosmidis, P; Mylonakis, N; Nikolaidis, C; Papaconstantinou, C; Papadimitriou, C; Pavlidis, N; Samantas, E; Skarlos, D	1
Burton, A; Chan, KK; Earl, HM; Jenkins, AH; Jordan, SD; Luesley, D; Mould, JJ; Perren, T; Poole, CJ; Spooner, DA; Sturman, S	1
Beijnen, JH; Koopman, FJ; Mandjes, IA; Meerum Terwogt, JM; Rocchetti, M; Rosing, H; Schellens, JH; Schot, M; ten Bokkel Huinink, WW; Zurlo, MG	1
Sparreboom, A; van Zuylen, L; Verweij, J	1
Beer, TM; Bubalo, JS	1
Beuzeboc, P; Diéras, V; Laurence, V; Pierga, JY; Pouillart, P	1
Bedikian, A; Desai, N; Ellerhorst, JA; Esmaeli, B; Hortobagyi, GN; Ibrahim, NK; Legha, S; Ring, SE; Rivera, E; Soon-Shiong, P; Theriault, RL	1
Depisch, D; Haider, K; Kornek, GV; Kovats, E; Kwasny, W; Lang, F; Payrits, T; Raderer, M; Scheithauer, W; Schüll, B	1
Feun, LG; Hurley, J; Marini, A; Savaraj, N	1
Apfel, SC; Arezzo, JC; Kessler, JA; Lipton, RB	1
Apfel, SC; Berger, A; Dutcher, JP; Einzig, AI; Kaplan, J; Lipton, RB; Rosenberg, R; Schaumburg, HH; Wiernik, P	1
Dutcher, JP; Einzig, A; Lipton, RB; Schwartz, EL; Strauman, JJ; Wiernik, PH	1
Donehower, RC; Ettinger, DS; Grochow, LB; Longnecker, SM; Rowinsky, EK	1

Reviews

9 review(s) available for paclitaxel and Nervous System Disorders

Article	Year
Beyond taxol: microtubule-based treatment of disease and injury of the nervous system. Brain : a journal of neurology, 2013, Volume: 136, Issue:Pt 10 Topics: Animals; Humans; Microtubule-Associated Proteins; Microtubules; Nervous System; Nervous System Diseases; Neurons; Paclitaxel	2013
Identification of candidate SNPs for drug induced toxicity from differentially expressed genes in associated tissues. Gene, 2012, Sep-10, Volume: 506, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bone Marrow; Carboplatin; Cell Cycle Proteins; Databases, Genetic; DNA-Binding Proteins; Female; Gene Expression; Genetic Markers; Lung Neoplasms; Male; Neoplasms; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Protein Serine-Threonine Kinases; Tumor Suppressor Proteins	2012
Paclitaxel (TAXOL): side effects and patient education issues. Seminars in oncology nursing, 1993, Volume: 9, Issue:4 Suppl 2 Topics: Drug Hypersensitivity; Heart; Humans; Leukopenia; Liver; Nervous System Diseases; Paclitaxel; Patient Education as Topic	1993
Overview of Taxol safety. Journal of the National Cancer Institute. Monographs, 1993, Issue:15 Topics: Bone Marrow; Cardiovascular Diseases; Drug Hypersensitivity; Humans; Nervous System Diseases; Paclitaxel	1993
Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer. Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:8 Suppl 8 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Synergism; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Neoplasm Metastasis; Nervous System Diseases; Paclitaxel; Remission Induction; Survival Rate; Taxoids; Vinblastine; Vinorelbine	1997
Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine. Seminars in oncology, 1999, Volume: 26, Issue:2 Suppl 7 Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytoprotection; Humans; Lung Neoplasms; Nervous System Diseases; Paclitaxel; Protective Agents; Randomized Controlled Trials as Topic	1999
Role of formulation vehicles in taxane pharmacology. Investigational new drugs, 2001, Volume: 19, Issue:2 Topics: Animals; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chemistry, Pharmaceutical; Cyclosporine; Drug Hypersensitivity; Drug Resistance, Multiple; Glycerol; Humans; Micelles; Neoplasms; Nervous System Diseases; Paclitaxel; Polysorbates; Surface-Active Agents	2001
Complications of chemotherapy for prostate cancer. Seminars in urologic oncology, 2001, Volume: 19, Issue:3 Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Docetaxel; Gastrointestinal Diseases; Humans; Male; Mitoxantrone; Nervous System Diseases; Paclitaxel; Prednisone; Prostatic Neoplasms; Taxoids	2001
Interaction between Herceptin and taxanes. Oncology, 2001, Volume: 61 Suppl 2 Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Heart Diseases; Humans; Mice; Mice, Nude; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Nervous System Diseases; Neutropenia; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptor, ErbB-3; Salvage Therapy; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Xenograft Model Antitumor Assays	2001

Trials

49 trial(s) available for paclitaxel and Nervous System Disorders

Article	Year
Blockade of IL-6 signaling prevents paclitaxel-induced neuropathy in C57Bl/6 mice. Cell death & disease, 2020, 01-22, Volume: 11, Issue:1 Topics: Animals; Animals, Newborn; Antibodies, Neutralizing; Cohort Studies; Female; Ganglia, Spinal; Humans; Interleukin-6; Male; Mice, Inbred C57BL; Middle Aged; Models, Biological; Nervous System Diseases; Paclitaxel; Rats; Sensory Receptor Cells; Signal Transduction	2020
Phase I trial of selenium plus chemotherapy in gynecologic cancers. Gynecologic oncology, 2018, Volume: 150, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Chemotherapy-Induced Febrile Neutropenia; DNA-Binding Proteins; Down-Regulation; Female; Gene Expression; Glutathione Peroxidase; Humans; Infections; Lung Diseases; Maximum Tolerated Dose; Middle Aged; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; RNA-Binding Proteins; Selenious Acid; Selenium; Selenoprotein P	2018
Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer. Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:6 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome	2013
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. The New England journal of medicine, 2013, Oct-31, Volume: 369, Issue:18 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Pancreatic Neoplasms	2013
Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients. Clinical lung cancer, 2015, Volume: 16, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Albumins; Bevacizumab; Biomarkers, Pharmacological; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caveolin 1; Contraindications; Drug Therapy, Combination; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nanoparticles; Neoplasm Staging; Nervous System Diseases; Paclitaxel; Stromal Cells; Survival Analysis	2015
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. The Lancet. Oncology, 2016, Volume: 17, Issue:8 Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemoradiotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Nervous System Diseases; Paclitaxel; Prognosis; Quality of Life; Radiotherapy, Adjuvant; Survival Rate	2016
Treatment of base of tongue cancer with paclitaxel, ifosfamide, and cisplatinum induction chemotherapy followed by chemoradiotherapy. The Laryngoscope, 2008, Volume: 118, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nervous System Diseases; Paclitaxel; Radiotherapy, Adjuvant; Survival Rate; Tongue Neoplasms	2008
Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study. Breast cancer research and treatment, 2011, Volume: 125, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Nervous System Diseases; Paclitaxel; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Time Factors; Treatment Outcome; United States	2011
Gemcitabine and paclitaxel combination as second-line chemotherapy in patients with small-cell lung cancer: a phase II study. Clinical lung cancer, 2013, Volume: 14, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Neutropenia; Paclitaxel; Small Cell Lung Carcinoma	2013
Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Sep-01, Volume: 30, Issue:25 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Mastectomy; Middle Aged; Multivariate Analysis; Nervous System Diseases; Paclitaxel; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States	2012
Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Diarrhea; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Nervous System Diseases; Paclitaxel; Survival Analysis; Treatment Outcome	2002
Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta oncologica (Stockholm, Sweden), 2002, Volume: 41, Issue:5 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cimetidine; Clemastine; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug Hypersensitivity; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Injections, Intravenous; Life Tables; Middle Aged; Muscular Diseases; Nervous System Diseases; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Premedication; Salvage Therapy; Survival Analysis; Treatment Outcome	2002
Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study. Medical oncology (Northwood, London, England), 2003, Volume: 20, Issue:3 Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cytoprotection; Female; Heart Diseases; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Prospective Studies; Protective Agents	2003
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jun-01, Volume: 22, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Nervous System Diseases; Paclitaxel; Proportional Hazards Models; Recombinant Proteins; Survival Analysis	2004
Gemcitabine and vinorelbine as second-line therapy for non-small cell lung cancer after treatment with paclitaxel plus platinum. Japanese journal of clinical oncology, 2004, Volume: 34, Issue:5 Topics: Adult; Aftercare; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Platinum; Survival Rate; Vinblastine; Vinorelbine	2004
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. Cancer, 2004, Aug-15, Volume: 101, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Paclitaxel; Quality of Life	2004
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Nov-15, Volume: 22, Issue:22 Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyglutamic Acid; Taxoids	2004
A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma. Gynecologic oncology, 2005, Volume: 97, Issue:1 Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Staging; Nervous System Diseases; Neuroprotective Agents; Neutropenia; Ovarian Neoplasms; Paclitaxel; Quality of Life	2005
Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum. Japanese journal of clinical oncology, 2005, Volume: 35, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Drug Administration Schedule; Endpoint Determination; Female; Fluorouracil; Humans; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Platinum; Stomach Neoplasms	2005
Phase I study of a weekly schedule of fixed-dose paclitaxel and escalating doses of cisplatin for recurrent or unresectable gastric cancer in Japan. American journal of clinical oncology, 2005, Volume: 28, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Feasibility Studies; Female; Gastrectomy; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Japan; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Treatment Outcome	2005
Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:12 Topics: Acetylcarnitine; Action Potentials; Administration, Oral; Adult; Aged; Antineoplastic Agents; Cisplatin; Female; Humans; Male; Middle Aged; Motor Neurons; Nervous System Diseases; Neurons, Afferent; Paclitaxel; Reaction Time	2005
Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors: preliminary results and promising directions. Seminars in oncology, 1995, Volume: 22, Issue:5 Suppl 12 Topics: Adult; Aged; Aged, 80 and over; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Premedication; Radiation-Sensitizing Agents; Regression Analysis; Survival Rate	1995
Paclitaxel-induced neuropathy. Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:5 Topics: Adult; Aged; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hand Strength; Humans; Incidence; Middle Aged; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Perception; Prospective Studies; Vibration	1995
A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:6 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Eruptions; Europe; Female; Humans; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Remission Induction; Taxoids	1994
Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:6 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Europe; Female; Humans; Leukopenia; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Remission Induction; Sarcoma; Soft Tissue Neoplasms; Taxoids; Thrombocytopenia	1994
Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:1 Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Drug Hypersensitivity; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Survival Rate; Treatment Outcome	1996
Re: Severe neurotoxicity in vinorelbine-paclitaxel combinations. Journal of the National Cancer Institute, 1997, Jan-01, Volume: 89, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Nervous System Diseases; Paclitaxel; Patient Selection; Vinblastine; Vinorelbine	1997
Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel--a phase II study. Cancer chemotherapy and pharmacology, 1996, Volume: 39, Issue:1-2 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Humans; Kidney; Middle Aged; Nervous System Diseases; Paclitaxel; Reflex; Salvage Therapy; Vinblastine; Vinorelbine	1996
Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. British journal of cancer, 1997, Volume: 75, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Nervous System Diseases; Paclitaxel; Paresthesia; Taxoids	1997
Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Fatigue; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Mucous Membrane; Neoplasm Metastasis; Nervous System Diseases; Paclitaxel	1997
A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma. Cancer, 1997, May-15, Volume: 79, Issue:10 Topics: Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Cohort Studies; Combined Modality Therapy; Female; Fever; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Nervous System Diseases; Neutropenia; Paclitaxel; Preoperative Care; Survival Rate; Thrombocytopenia	1997
Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis. Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 15 Topics: Adult; Aged; Ambulatory Care; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow; Carboplatin; Carcinoma; Cisplatin; Female; Follow-Up Studies; Hospitalization; Humans; Incidence; Infusions, Intravenous; Middle Aged; Nausea; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Remission Induction; Survival Rate; Vomiting	1997
Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma. Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 15 Topics: Administration, Oral; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Transitional Cell; Confidence Intervals; Disease Progression; Drug Administration Schedule; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leucovorin; Male; Methotrexate; Middle Aged; Neoplasm Staging; Nervous System Diseases; Neutropenia; Paclitaxel; Remission Induction; Salvage Therapy; Sepsis; Urinary Bladder Neoplasms	1997
Phase I trial of weekly paclitaxel in advanced lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nervous System Diseases; Neutropenia; Paclitaxel	1998
Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:1 Topics: Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Urologic Neoplasms	1998
Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Female; Hematopoietic Stem Cell Mobilization; Humans; Melphalan; Middle Aged; Neoplasm Staging; Nervous System Diseases; Neutropenia; Paclitaxel; Thiotepa; Treatment Outcome	1998
Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer investigation, 1998, Volume: 16, Issue:7 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Sarcoma	1998
A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:10 Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Edema; Female; Fever; Humans; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Taxoids	1998
Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel. Anti-cancer drugs, 1998, Volume: 9, Issue:9 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Docetaxel; Female; Glucocorticoids; Humans; Male; Middle Aged; Neoplasms; Nervous System Diseases; Paclitaxel; Prospective Studies; Taxoids	1998
Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:3 Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nervous System Diseases; Paclitaxel; Survival Analysis; Uterine Cervical Neoplasms	1999
Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer. British journal of cancer, 1999, Volume: 80, Issue:7 Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Leukopenia; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Thrombocytopenia	1999
Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours. British journal of cancer, 2000, Volume: 82, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasms; Nervous System Diseases; Neutropenia; Outpatients; Paclitaxel; Taxoids; Thrombocytopenia	2000
Paclitaxel in advanced non-small cell lung cancer : an alternative high-dose weekly schedule. Chest, 2000, Volume: 117, Issue:4 Suppl 1 Topics: Aged; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Nervous System Diseases; Neutropenia; Paclitaxel; Platelet Count; Radiation-Sensitizing Agents	2000
Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG). Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Prognosis; Survival Analysis; Treatment Outcome	2000
Phase II clinical trials of cisplatin-then-paclitaxel and paclitaxel-then-cisplatin in patients with previously untreated advanced epithelial ovarian cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:12 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel	2000
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anti-cancer drugs, 2001, Volume: 12, Issue:4 Topics: Adult; Aged; Anemia; Area Under Curve; Breast Neoplasms; Carcinoma, Small Cell; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Carriers; Female; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Methacrylates; Middle Aged; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Polymers; Prodrugs; Remission Induction; Skin Neoplasms; Solubility; Taxoids	2001
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Area Under Curve; Castor Oil; Chemistry, Pharmaceutical; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Nervous System Diseases; Paclitaxel; Particle Size; Stomatitis; Taxoids; Treatment Outcome	2002
Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:5 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Fatigue; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Nausea; Nervous System Diseases; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome	2002
Phase II trial of Paclitaxel and Dacarbazine with filgrastim administration in advanced malignant melanoma. Cancer investigation, 2002, Volume: 20, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Nervous System Diseases; Paclitaxel; Skin Neoplasms; Treatment Outcome	2002

Other Studies

16 other study(ies) available for paclitaxel and Nervous System Disorders

Article	Year
Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases. Bulletin du cancer, 2021, Volume: 108, Issue:3 Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Digestive System Diseases; Docetaxel; Fatigue; Female; Fluorouracil; Hematologic Diseases; Humans; Male; Middle Aged; Nail Diseases; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Taxoids; Tunisia	2021
Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions. Journal of gynecologic oncology, 2017, Volume: 28, Issue:4 Topics: Adult; Aged; Albumins; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Drug Hypersensitivity; Female; Gemcitabine; Genital Neoplasms, Female; Humans; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Retreatment; Retrospective Studies; Taxoids; Thrombocytopenia	2017
Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study. Seminars in oncology, 2017, Volume: 44, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neurotoxicity Syndromes; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Progression-Free Survival; Republic of Korea; Survival Rate; Treatment Outcome	2017
Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma. Oncology, 2010, Volume: 78, Issue:5-6 Topics: Anemia; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Neoplasm Staging; Nervous System Diseases; Neutropenia; Ovarian Neoplasms; Paclitaxel; Survival Rate; Thrombocytopenia	2010
Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast cancer research and treatment, 2011, Volume: 125, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Cross-Sectional Studies; Female; Humans; Hypesthesia; Middle Aged; Nervous System Diseases; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Taxoids	2011
GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients. Acta oncologica (Stockholm, Sweden), 2013, Volume: 52, Issue:4 Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Extracellular Matrix Proteins; Female; Genetic Predisposition to Disease; Genome-Wide Association Study; GPI-Linked Proteins; Humans; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Reproducibility of Results; Retrospective Studies; Scandinavian and Nordic Countries; Validation Studies as Topic	2013
The ACTH-(4-9) analog, ORG 2766, prevents taxol-induced neuropathy in rats. European journal of pharmacology, 1993, Mar-16, Volume: 233, Issue:1 Topics: Adrenocorticotropic Hormone; Animals; Anticonvulsants; Male; Nervous System Diseases; Neural Conduction; Paclitaxel; Peptide Fragments; Rats; Rats, Wistar	1993
Docetaxel neuropathy. Neurology, 1996, Volume: 46, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Nervous System Diseases; Paclitaxel; Taxoids	1996
The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gynecologic oncology, 1996, Volume: 61, Issue:1 Topics: Adult; Aged; Cisplatin; Diabetes Complications; Diabetic Neuropathies; Female; Hearing Loss, Sensorineural; Humans; Hyperglycemia; Kidney; Middle Aged; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Sensation	1996
Docetaxel neuropathy. Neurology, 1996, Volume: 47, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Nervous System Diseases; Paclitaxel; Taxoids	1996
Unexpected incidence of neurotoxicity. Gynecologic oncology, 1997, Volume: 66, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Incidence; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel	1997
Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays. Cancer chemotherapy and pharmacology, 1999, Volume: 44, Issue:4 Topics: Animals; Antineoplastic Agents; Cell Division; Depsipeptides; Drug Screening Assays, Antitumor; Growth Inhibitors; Humans; Male; Nervous System Diseases; Oligopeptides; Paclitaxel; PC12 Cells; Peptides, Cyclic; Prostatic Neoplasms; Pyrans; Rats; Spiro Compounds; Tumor Cells, Cultured; Vinblastine; Vincristine; Vinorelbine	1999
Nerve growth factor prevents toxic neuropathy in mice. Annals of neurology, 1991, Volume: 29, Issue:1 Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Behavior, Animal; Electrophysiology; Ganglia, Spinal; Injections, Intraperitoneal; Male; Mice; Nerve Growth Factors; Nervous System Diseases; Neural Conduction; Neurons, Afferent; Paclitaxel; Reaction Time; Substance P	1991
Taxol produces a predominantly sensory neuropathy. Neurology, 1989, Volume: 39, Issue:3 Topics: Adult; Aged; Alkaloids; Female; Humans; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Sensation	1989
Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:8 Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Cimetidine; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Evaluation; Drug Hypersensitivity; Humans; Infusions, Intravenous; Kinetics; Melanoma; Neoplasms; Nervous System Diseases; Neutropenia; Paclitaxel	1987
Phase I trial of taxol in patients with advanced cancer. Cancer treatment reports, 1987, Volume: 71, Issue:12 Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Blood Cell Count; Dose-Response Relationship, Drug; Drug Evaluation; Drug Hypersensitivity; Hematopoiesis; Humans; Nervous System Diseases; Paclitaxel; Pharmaceutical Vehicles	1987